SNSE - Sensei Biotherapeutics Inc

SNSE - Sensei Biotherapeutics Inc

https://www.senseibio.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

GlobeNewswire • 1 month, 2 weeks ago • score: -0.20

BOSTON, July 30, 2025 ( GLOBE NEWSWIRE ) -- Sensei Biotherapeutics, Inc. ( NASDAQ: SNSE ) , a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, announced today that clinical data from the dose expansion cohort of ...

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025 - Sensei Biotherapeutics ( NASDAQ:SNSE )

Benzinga • 1 month, 2 weeks ago • score: -0.18

BOSTON, July 30, 2025 ( GLOBE NEWSWIRE ) -- Sensei Biotherapeutics, Inc.

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference - Sensei Biotherapeutics ( NASDAQ:SNSE )

Benzinga • 5 months, 1 week ago • score: -0.18

BOSTON, April 02, 2025 ( GLOBE NEWSWIRE ) -- Sensei Biotherapeutics, Inc.

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

GlobeNewswire • 5 months, 1 week ago • score: -0.19

BOSTON, April 02, 2025 ( GLOBE NEWSWIRE ) -- Sensei Biotherapeutics, Inc. ( Nasdaq: SNSE ) , a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, is dedicated to the discovery and development of therapies with an initial focus on cancer treatments. The company is headquartered in Rockville, Maryland.

52W High

$17.40

52W Low

$5.00

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.27

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

1.36

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

0.38

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

34.14%

Institutions (25–75% balanced)

5.65%

Shares Outstanding

1,261,300

Float

828,300

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-21.29

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.68%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.2992

Previous

0.2635

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025